Nuwellis: 92% Survival in Kids with Kidney Injury, Failure
Topline: In a multicenter registry of 91 critically ill pediatric patients treated with the Aquadex ultrafiltration system, 92% survived...
Silexion Data Shows Powerful 99.7% KRAS Cancer Inhibition
Silexion reported new preclinical data showing its RNAi candidate SIL204 inhibited proliferation by 83.5% to 99.7% across 11 human...
Vivex RESTORE Trial: A New Hope for Degenerative Disc Disease
Vivex Biologics has dosed the first patient in Restore, a randomized, double‑blind, sham‑controlled U.S. trial of VIA Disc NP...
Compelling Cellectar Data: A Soaring Hope for Kids’ Cancer
In an interim readout from the Phase 1b CLOVER-2 study in relapsed/refractory pediatric high-grade glioma (pHGG), patients receiving at...
Reunion Doses First Patient in Phase 2 Cancer Trial
Reunion Neuroscience’s RECONNECT Phase 2 trial in postpartum depression met its primary endpoint with a clinically meaningful reduction in...
Kynexis Doses First Patient in Phase 2 Schizophrenia Trial
Phase 1 data for KYN-5356 showed an acceptable safety and tolerability profile, adequate CNS penetration, dose-dependent reductions of kynurenic...
Positive Data in Eupraxia’s Highest-Dose Esophagitis Trial
Early signals from the highest planned dose in Eupraxia’s RESOLVE study point to stronger efficacy without new safety concerns....
Abivax ABTECT Phase 3 Trial Data Accepted at UEG Meeting
No numerical results were disclosed, but Abivax said its two Phase 3, 8‑week induction trials in moderately to severely...
Pivotal Ziftomenib AML Trial Launches, Doses First Patient
No new efficacy data were disclosed. The registrational Phase 3 program will test ziftomenib in two frontline settings with...
Promising Dyne Drug for Duchenne Gets Rare Japan Status
Dyne’s Phase 1/2 DELIVER trial of DYNE-251 has selected a registrational dose of 20 mg/kg administered every four weeks...